Dr. Schweizer discusses her journey as a scientist, executive, and founder of HiFiBiO as she leads the advancement of a pipeline of antibody drugs in cancer, autoimmune diseases, and COVID-19.
CAMBRIDGE, Mass. – March 11, 2021 – HiFiBiO Therapeutics CEO Liang Schweizer interviewed with Lioness Magazine to share how the company is combining its deep-rooted biological expertise with comprehensive single-cell profiling technologies to advance a pipeline of antibody drugs. Dr. Schweizer also highlights the importance of community service, volunteering, and mentorship in contributing to her successes.
Check out the interview video here!
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company’s strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai, and Hong Kong. To learn more, please visit www.hifibio.com.
HiFiBiO Therapeutics and the HiFiBiO Therapeutics logo, and DIS® are trademarks of HiFiBiO and its affiliates.